These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36596363)

  • 21. Treatment of Peyronie's disease with intralesional verapamil injection.
    Levine LA
    J Urol; 1997 Oct; 158(4):1395-9. PubMed ID: 9302129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location.
    Stewart CA; Yafi FA; Knoedler M; Mandava SH; McCaslin IR; Sangkum P; Sikka S; Trost L; Hellstrom WJ
    J Urol; 2015 Dec; 194(6):1704-7. PubMed ID: 26144333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease.
    Seftel AD
    J Urol; 2016 May; 195(5):1562-1563. PubMed ID: 27186764
    [No Abstract]   [Full Text] [Related]  

  • 24. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease.
    Cavallini G; Modenini F; Vitali G
    Urology; 2007 May; 69(5):950-4. PubMed ID: 17482941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease.
    Moskovic DJ; Alex B; Choi JM; Nelson CJ; Mulhall JP
    BJU Int; 2011 Nov; 108(9):1485-9. PubMed ID: 21733073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease.
    Cavallini G; Biagiotti G; Koverech A; Vitali G
    BJU Int; 2002 Jun; 89(9):895-900. PubMed ID: 12010235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Collagenase Clostridium histolyticum (Xiapex
    Cocci A; Di Maida F; Russo GI; Capogrosso P; Francesco L; Rizzo M; Di Mauro M; Salonia A; Cito G; Falcone M; Romano A; Polloni G; Martinez-Salamanca JI; Fernández-Pascual E; Minervini A; Mondaini N
    Clin Drug Investig; 2020 Jun; 40(6):583-588. PubMed ID: 32342279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of local injections treatments for Peyronie's disease: Review of the literature].
    Rod X; Akakpo W; Roupret M
    Prog Urol; 2021 Dec; 31(16):1072-1079. PubMed ID: 34148769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease.
    Mehrsai AR; Namdari F; Salavati A; Dehghani S; Allameh F; Pourmand G
    Andrology; 2013 Jan; 1(1):129-32. PubMed ID: 23258641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with intraplaque injection of verapamil for Peyronie's disease.
    Levine LA; Goldman KE; Greenfield JM
    J Urol; 2002 Aug; 168(2):621-5; discussion 625-6. PubMed ID: 12131321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
    Jordan GH
    J Sex Med; 2008 Jan; 5(1):180-7. PubMed ID: 18173766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
    Levine LA; Cuzin B; Mark S; Gelbard MK; Jones NA; Liu G; Kaufman GJ; Tursi JP; Ralph DJ
    J Sex Med; 2015 Jan; 12(1):248-58. PubMed ID: 25388099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of current nonsurgical management of Peyronie's disease.
    Levine LA
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S113-20. PubMed ID: 14551587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical analysis of nonsurgical treatment of Peyronie's disease.
    Hauck EW; Diemer T; Schmelz HU; Weidner W
    Eur Urol; 2006 Jun; 49(6):987-97. PubMed ID: 16698449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease.
    Ahuja S; Bivalacqua TJ; Case J; Vincent M; Sikka SC; Hellstrom WJ
    J Androl; 1999; 20(4):444-8. PubMed ID: 10452584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial.
    Greenfield JM; Shah SJ; Levine LA
    J Urol; 2007 Mar; 177(3):972-5. PubMed ID: 17296390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intralesional interferon-alpha-2b for the treatment of Peyronie's disease.
    Lacy GL; Adams DM; Hellstrom WJ
    Int J Impot Res; 2002 Oct; 14(5):336-9. PubMed ID: 12454683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease.
    Russell S; Steers W; McVary KT
    Eur Urol; 2007 Mar; 51(3):640-7. PubMed ID: 17092631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study.
    Favilla V; Russo GI; Privitera S; Castelli T; Madonia M; La Vignera S; Condorelli R; Calogero AE; Farina FP; Cimino S; Morgia G
    Andrologia; 2014 Oct; 46(8):936-42. PubMed ID: 24124921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten-year experience with multimodal treatment for acute phase Peyronie's disease: A real life clinical report.
    Gallo L; Sarnacchiaro P
    Actas Urol Esp (Engl Ed); 2019 May; 43(4):182-189. PubMed ID: 30704797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.